Mankind Pharma’s Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 17%, exports more than doubled, and consumer health grew 30%.
Following a ceasefire announcement by Pakistan’s military, the KSE 100 index surged over 9% after facing pressure due to escalating India-Pakistan tensions and recent terrorist
Reliance Power reported a consolidated net profit of Rs 126 crore for Q4 FY25, a significant turnaround from the previous year’s loss, driven by reduced
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003